It doesn't look that way on my end. I might have to check with the support people. Does anyone else see "invalid handle"?

More evidence of the pervasiveness of publication bias. Article:

"Publication Bias in Coronary Artery Disease Clinical Trials: A Bibliometric Review" pubmed.ncbi.nlm.nih.gov/41999643/
"The publication rate for positive studies was 92%, whereas for negative studies it was 50% (P<0.001)."

Psychedelic drug policy via podcaster influence. @garyschw.bsky.social, quoting @statnews.com: "Rogan said he texted Trump about research around ibogaine, and the president’s response was quick: 'Sounds great. Do you want FDA approval? Let’s do it.'" garyschwitzer.substack.com?utm_campaign...

Hopefully we'll C some teeth following this overly gentle "reminder". This FDA bulletin www.fda.gov/news-events/... mentions a Mar 30 message to trial sponsors intended to "provide...the opportunity to comply", hinting at poss "further regulatory action". Nice, but the FDA need not B so obsequious.

you’ll never guess the total cost 😅 AAD dermatology conference skincare haul TikTok video by Michael Park, MD

This guy picked up nearly $4000 worth of "goodies" at a dermatology conference. Multiply that by thousands of conference attendees. Yet only a fraction of what these companies spend on marketing. Just witness the plethora of ads for very expen$I've derm drugs on TV
www.tiktok.com/@dr.michaelp...

Makary seems to be acting like this is a new thing that he's *asking* drug companies to do, as if (a) it was his idea first, when you have been a leader on this question for MANY years, eg with FDA Trials Tracker fdaaa.trialstracker.net and (b) it's not a legal requirement already.

F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials

Sorry, I thought everyone was allowed 10 free articles per month, but apparently each subscriber is allowed to gift (verb) 10 articles per month.

Try this link: www.nytimes.com/2026/04/13/w...

The article doesn't define "publish", ie whether in a journal vs posting on ClinicalTrials.gov

Judge tosses lawsuit over controversial Paxil ‘Study 329’ A judge has dismissed a legal challenge aimed at forcing Elsevier to retract a long-criticized study that concluded the antidepressant Paxil was safe and effective for teens. The 2001 paper, publis…

www.doximity.com/newsfeed/c46...

F.D.A. Pushes Drug Developers to Report Clinical Trial Results

F.D.A. Pushes Drug Developers to Report Clinical Trial Results www.nytimes.com/2026/04/13/w...

Now is the time to act on 32 FDA transparency reforms, experts say in JAMA

www.cspi.org/press-releas...

BMJ Open article: "Substantial undisclosed financial COIs were identified among the top 10 earners in high-impact psychiatry journals."
bmjopen.bmj.com/content/15/1...

Prasad’s Request To Remain Anonymous Shines Light on FDA’s Transparency Problem While requests by government officials for anonymity when speaking to the media are nothing new, the practice attracts more scrutiny when the Department for Health and Human Services has pledged a com...

Here's an article on this topic: www.biospace.com/fda/prasads-...

Vinay Prasad MD MPH Inactive account - Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Research (CBER) at the US FDA. The videos on this platform were posted before my FDA employment...

He deactivated his YouTube channel (www.youtube.com/@vprasadmdmph) when he went to the FDA, but perhaps he'll start it back up and we'll hear more about this resignation.

Divisive F.D.A. Vaccine Regulator Resigns

Vinay Prasad resigns from the FDA. Well, he did resign in August but was brought back in a few days, but maybe this time it's for real.

www.nytimes.com/2026/03/06/h...

Makary apparently wants his FDA reviewers to be about as thorough as the "security guard" in this meme.

The speed of the the reviews is already plenty fast due to mandated deadlines for completing the reviews. This is just going to incentivize reviewers to reduce scrutiny, potentially missing serious problems

Hey, here's a thought...
How about offering bonus payments for staffers who complete CORRECT reviews and recommend approval ONLY if the drugs are truly safe and effect?

FDA to offer bonus payments to staffers who complete speedy drug reviews The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule.

apnews.com/article/drug... to offer bonus payments to staffers who complete speedy drug reviews

FDA will drop two-study requirement for new drug approvals, aiming to speed access The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals.

This could be extremely harmful. False positives, power issues, & rare adverse events come to mind if there is only one trial required 🤦‍♀️

or donate to the ballroom or T-Kennedy Center projects or etc, etc

Note there's a tiny study w N= 11 x 2 = 22 that was published with positive results. If a similarly-size study yielded negative results, something tells me that the investigators and/or journals would have been dismissed it as underpowered and not worth publishing.

Yep, an SMD of 1.8 for any antidepressant is hard to believe. Seems more like what you'd get for open-label (placebo-free) studies. I'd suspect outcome switching and/or burying other studies with less over-the-moon results.

STAT piece first-authored be @lizzylawrence.bsky.social. Perhaps she has insight into the politics.

I can’t imagine RFK Jr NOT supporting a psychedelic, so was this a defeat for him?

(Apologies if this is addressed in the full text of the article, but I lack access.)

Last summer, RFK Jr criticized the FDA for not approving MDMA-assisted psychotherapy for PTSD. Now that he's been given power over the FDA, I figured that any psychedelic would be on a glide path to approval this year. But apparently not!

Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe depression, STAT has learned.

It seems that decisions at the FDA can go either way based on a combination of science and politics.
www.statnews.com/2026/02/04/p...

Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies Anti-amyloid drugs modestly slow Alzheimer’s disease progression, albeit with uncertainty of sustained benefit, particularly as they cause paradoxical acceleration of brain volume changes. Here, we ex...

Article: Missing data about missing tissue ⬇️
dx.plos.org/10.1371/jour...

Misleading Readers without Lies: Understanding Spin and its Relevance to Acupuncture Research This article provides an overview of spin in general and the current state of spin research in acupuncture studies. We introduce the definition and hi…

Nice article, providing an overview of the various types of spin:

Although the article relates spin to research on acupuncture, it applies to research in general.

www.sciencedirect.com/science/arti...

This “stellar groups” has a North Star…@floriannaudet.bsky.social An honor to be helping shine some additional light!

Finally, good to see that they not only used a sham control but also tested whether blinding was successful. Apparently, it wasn't great (screenshot), raising the Q of whether that could have biased the participants and investigators, so the positive results should be taken with a grain of salt

Kudos also to the authors or reviewers for showing not only P values but also effect sizes (Cohen's d). On the primary outcome--the most important result-- they found d = 0.37. That's in the upper end of the range for second-generation antidepressants, but not worthy of hyping it as a "breakthrough"